Spare Change of Mind tracks psychedelic science, companies, policy, source trails, and research infrastructure with careful caveats.
The project is part reporting desk, part field guide, and part living notebook for a field where ancient substances, modern drug development, public policy, venture capital, and spiritual history keep colliding. The goal is simple: make the map easier to read without sanding off the uncertainty.
News / posts
Timely explainers with a source spine.
Posts cover trial readouts, company moves, policy shifts, source disputes, and cultural moments. The best pieces are not just “what happened” — they explain which claims are primary-source backed, which are company language, and which are still unresolved.
The wiki is where recurring compounds, people, companies, programs, regulators, and source lanes become stable reference entries. It is meant to keep the next article cleaner: less re-explaining, more context at the right depth.
The changelog keeps the site honest about its own edits: new dossiers, revised explainers, source-integrity passes, layout improvements, and other visible changes that matter to readers following the project over time.
Psychedelic coverage can get overheated fast. Spare Change of Mind tries to stay useful by separating the layers: compound, formulation, company program, trial record, regulatory status, cultural history, and reader takeaway.
Use primary sources where possible: registries, papers, statutes, regulator pages, company filings, and direct releases.
Do not turn announced, selected, proposed, or funded-in-concept into contracted, enrolling, running, approved, or proven.
Preserve uncertainty instead of pretending every source has the same weight.
Avoid hype, but do not flatten the field into cynicism either. Some of the work is genuinely interesting.
Reader note
This is not medical advice.
Spare Change of Mind is for reporting, reference, and source-aware learning. It is not a treatment guide, a recommendation to use any substance, or a substitute for care from a qualified clinician. When a page discusses a trial, therapy model, or compound, read it as a map of the public record — not a personal medical instruction.